Oropharyngeal epstein‐barr virus excretion in rheumatoid arthritis

We hypothesized that the defective cellular regulation of Epstein‐Barr virus (EBV) in rheumatoid arthritis (RA) might be reflected in an increased rate of oropharyngeal virus excretion, but we found that the prevalence of excretion in 45 RA patients (22%) did not differ from 45 age‐ and sex‐matched...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis and rheumatism 1982-04, Vol.25 (4), p.427-431
Main Authors: Depper, Joel M., Zvaifler, Nathan J., Bluestein, Harry G.
Format: Article
Language:English
Subjects:
Adrenal Cortex Hormones - therapeutic use
Anti-Inflammatory Agents - therapeutic use
Antibodies, Viral - analysis
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - metabolism
Epstein-Barr virus
Female
Herpesvirus 4, Human - immunology
Herpesvirus 4, Human - metabolism
Humans
Male
Middle Aged
Mouth - microbiology
Pharynx - microbiology
Prednisone - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We hypothesized that the defective cellular regulation of Epstein‐Barr virus (EBV) in rheumatoid arthritis (RA) might be reflected in an increased rate of oropharyngeal virus excretion, but we found that the prevalence of excretion in 45 RA patients (22%) did not differ from 45 age‐ and sex‐matched non‐RA patients (24%) who were taking similar medications. Increased excretion rates correlated with corticosteroid therapy and male sex, but not with age or serum levels of EBV antibodies.
ISSN:0004-3591
1529-0131
DOI:10.1002/art.1780250411